ADAP Overview
Upcoming Projects (ADAP)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (ADAP)
-
Don’t see a project related to the company you care about? Create your own!
Expired Projects (ADAP)
-
Discussing Adaptimmune’s SPEAR T-cell therapies targeting MAGE-A10, MAGE-A4, and AFP
Ticker: ADAP
Execute By: Apr 10, 2020
Upcoming & Overdue Catalysts (ADAP)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (ADAP)
-
Adaptimmune’s Investor Day (virtual) Nov 20, 2020
Ticker: ADAP
Occurred on: Nov 20, 2020 -
Adaptimmune (ADAP) Provides Full Contents of its SITC Abstract for the Phase 1 SURPASS Trial
Ticker: ADAP
Occurred on: Oct 15, 2020 -
Adaptimmune (ADAP) Announces Results from the SPEAR T-cell Platform in Four Solid Tumor Indications
Ticker: ADAP
Occurred on: Jan 13, 2020 -
Adaptimmune Announces Partial Clinical Hold of Planned Pivotal Study of NY-ESO SPEAR T-cell Therapy in Myxoid Round Cell Liposarcoma
Ticker: ADAP
Occurred on: Aug 03, 2016
Strategic Initiatives (ADAP)
-
Adaptimmune (ADAP) Announces Five-Year Manufacturing Partnership with PCT Biosciences (CLBS) for SPEAR T-Cell Therapies
Tickers: ADAP, CLBS
Announcement Date: Sep 19, 2016
